| Original language | English |
|---|---|
| Pages (from-to) | 5-7 |
| Number of pages | 3 |
| Journal | Lancet |
| Volume | 399 |
| Issue number | 10319 |
| Early online date | 15 Dec 2021 |
| DOIs | |
| Publication status | Published - 1 Jan 2022 |
Bibliographical note
Funding Information:ZM declares no competing interests. Related to the topic, CAB has received speaker's fees from Bayer for non-promotional education and conference funding from Bayer to present research data unrelated to rivaroxaban. Unrelated to the topic, CAB has received speaker's fees from Amgen, Bristol Myers Squibb/Pfizer Alliance, Janssen, Eli Lilly, and Novartis; support to attend conferences from Amgen and Novartis; and advisory fees from Ablynx, Bristol Myers Squibb/Pfizer Alliance, Lilly, Novartis, and Portola.
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver